Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hepion Pharmaceuticals (HEPA)
:HEPA
Holding HEPA?
Track your performance easily
HEPA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.43 - $3.49
Previous Close$0.56
Volume20.84K
Average Volume (3M)78.23K
Market Cap
$3.26M
Enterprise ValueN/A
Total Cash (Recent Filing)$12.98M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.39
Shares Outstanding6,958,371
10 Day Avg. Volume155,246
30 Day Avg. Volume78,232
Standard Deviation0.29
R-Squared0.09
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Hepion Pharmaceuticals News
PremiumCompany Announcements
Hepion Pharmaceuticals Terminates Merger with Pharma Two B
Ownership Overview
0.27%
Insiders
1.88% Mutual Funds
3.33% Other Institutional Investors
93.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HEPA FAQ
What was Hepion Pharmaceuticals’s price range in the past 12 months?
Hepion Pharmaceuticals lowest stock price was $0.43 and its highest was $3.49 in the past 12 months.
What is Hepion Pharmaceuticals’s market cap?
Hepion Pharmaceuticals’s market cap is $3.26M.
When is Hepion Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hepion Pharmaceuticals’s earnings last quarter?
Hepion Pharmaceuticals released its earnings results on May 15, 2018. The company reported -$16.8 earnings per share for the quarter, missing the consensus estimate of N/A by -$16.8.
Is Hepion Pharmaceuticals overvalued?
According to Wall Street analysts Hepion Pharmaceuticals’s price is currently Overvalued.
Does Hepion Pharmaceuticals pay dividends?
Hepion Pharmaceuticals does not currently pay dividends.
What is Hepion Pharmaceuticals’s EPS estimate?
Hepion Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hepion Pharmaceuticals have?
Hepion Pharmaceuticals has 6,958,371 shares outstanding.
What happened to Hepion Pharmaceuticals’s price movement after its last earnings report?
Hepion Pharmaceuticals reported an EPS of -$16.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Hepion Pharmaceuticals?
Currently, no hedge funds are holding shares in HEPA
---
Company Description
Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
---
Technical Analysis
Achieve Life Sciences
―
180 Life Sciences
―
Can-Fite BioPharma
―
Cyclerion Therapeutics
―
ESSA Pharma
―
Axsome Therapeutics
―
---